Curium commits €32M to scale prostate cancer radioligand therapy at Saclay
What's the deal? CuriumDealroom has a profile for this one. Try Dealroom →, a global leader in nuclear medicine, is investing over €32 million at its historic site in Saclay, France, to build a new production line for a targeted prostate cancer therapy. The company announced the move at the Choose France summit in Versailles on June 1.
The new facility will produce ¹⁷⁷Lu-PSMA-I&T, a radioligand therapy (RLT) for patients with metastatic castration-resistant prostate cancer. The investment will create 20 highly skilled jobs and supply the European market.
The move marks Curium's shift from a purely diagnostic focus to a "theranostic" model — combining diagnostics with targeted treatments. France accounts for more than 20% of Curium's global revenue, and the company already operates 13 production sites and employs over 750 people in the country.
Why now? The radioligand therapy market is expected to grow tenfold by 2035, driven by a surge in eligible patients and advances in targeted cancer treatment. Curium has invested more than €50 million in France over the past five years, and this latest commitment signals it wants to scale quickly ahead of that growth wave.
"Radioligand therapy in particular is set to become an essential component of the modern therapeutic arsenal against cancer," said chief executive officer Ciril Faia.
Saclay was chosen for its world-class scientific ecosystem, rooted in the legacy of the French Atomic Energy Commission (CEA).
What could go wrong? Radiopharmaceutical manufacturing is complex and heavily regulated. Building a new production line for a therapeutic agent requires navigating stringent quality and safety approvals across multiple European markets. Any regulatory delays could slow the timeline and limit Curium's ability to meet rising demand.
The therapy itself targets a specific subset of prostate cancer patients, meaning the addressable market — while growing fast — remains relatively narrow compared with broader oncology treatments.
The signal: Curium's €32 million manufacturing bet arrives as the radioligand therapy space heats up globally, with major pharma players racing to secure production capacity for a market projected to grow tenfold by 2035. For a company that Dealroom still classifies as "early growth," the shift from diagnostics into full-scale therapeutic manufacturing represents a significant strategic leap — and a sign that Europe's radiopharmaceutical supply chain is maturing from research-stage promise into industrial-scale reality.
Read more: finanznachrichten.de
